Brussels, Belgium
Brussels, Belgium

Time filter

Source Type

DUBLIN, Apr. 25, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Clinical Chemistry Analyzers Market Analysis By Product (Analyzers, Reagents), By Test (BMP, Electrolyte Panel, Liver Panel, Lipid Profile, Renal Profile, Thyroid Function Profile, Specialty...


The global clinical chemistry analyzers market is expected to reach USD 16.0 billion by 2025 The growing prevalence of chronic diseases is anticipated to be responsible for the high urgency to adopt clinical chemistry analyzers, which thereby widens the scope for growth during the forecast period. In addition, growing base of geriatric and bariatric population, which is highly susceptible to chronic diseases, is presumed to impel the demand further. Consequently, the resultant high sample volume requiring high capability analyzing devices is driving the market growth. Moreover, increasing awareness pertaining to benefits associated with these devices is also a high impact rendering driver for clinical chemistry analyzers market. Advent of advanced chemistry analyzers has resulted in improved point-of-care testing capabilities, and thus created high potential growth opportunities for the market. In addition, technological advancements in preanalytical, analytical, and post analytical stages due to analyzing devices & reagents improved their diagnostic capabilities and overall efficiency, which is predicted to propel the growth further. These advancements include advent of microchips, sensors, chemometrics, and robotics. Furthermore, consistent efforts by public as well private healthcare organizations to increase the reliability of data have rapidly engendered the integration of automated chemistry analyzers and immunoassay systems, thereby resulting in overall reduction of workload in laboratories, thus propelling the demand. Further Key Findings From the Study Suggest: 4 Clinical Chemistry Analyzers Market: Product Estimates & Trend Analysis 4.1 Clinical Chemistry Analyzers Market: Product Movement Analysis 4.2 Analyzers 4.2.2 Small analyzers 4.2.3 Medium analyzers 4.2.4 Large analyzers 4.2.5 Very large analyzers 4.3 Reagents 4.3.2 Calibrators 4.3.3 Controls 4.3.4 Standards 4.3.5 Others 4.4 Others For more information about this report visit http://www.researchandmarkets.com/research/kbqjgr/clinical Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-clinical-chemistry-analyzers-market-analysis-2014-2017--2025-key-players-are-mindray-medical-international-johnson--johnson-and-fhoffmann-la-roche-300444290.html


News Article | April 17, 2017
Site: www.prweb.com

Visiun is pleased to announce the formation of a new Advisory Board, bringing together experts in the laboratory industry to provide input and perspective to the fast-changing environment of the hospital laboratory and Visiun’s leading laboratory analytics tool, Performance Insight™. The first member of the newly formed panel is Denise Uettwiller-Geiger, Ph.D., DLM(ASCP), award-winning Clinical Chemist, Director of Clinical Trials at John T Mather Hospital, and author of more than 80 clinical journal articles. Dr. Uettwiller-Geiger works in a laboratory that processes more than 2.4 million tests per year, assists with new technology and menu expansion, and serves as principal investigator for clinical trials in the areas of infectious disease, cardiac, point of care, and other new technologies. She also provides expert education, guidance and consultation to clinicians. As the first member of Visiun’s Advisory Board, Dr. Uettwiller-Geiger will use her expertise to provide strategic advice and recommendations to the expansion of Performance Insight and how it can best support laboratory management in improving operational performance most effectively. “Visiun is pleased to welcome Dr. Uettwiller-Geiger as the first member of our new Advisory Panel,” says Tom Joseph, Visiun President and CEO. “We look forward to working with Dr. Uettwiller-Geiger and receiving thoughtful guidance and recommendations from an industry leader like herself so we can best serve the laboratory community.” Dr. Uettwiller-Geiger received her Master of Health Sciences and an Advanced Certificate in Health Care Management, from the W. Averall Harriman School for Policy and Management, from Stony Brook University, Stony Brook, New York, and a PhD in Biomedical Science from Pacific Western University, Brentwood, California. In 2010, she received the American Association of Clinical Chemistry (AACC) Management Sciences Abstract Award for Outstanding Project; the National Academy of Clinical Biochemistry (NACB) Distinguished Abstract Award; and the Brookhaven’s Women’s Recognition Award for Science. In 2011, she received the Best Lab Practice Award from American Society of Clinical Pathology (ASCP) and the Siemens 2011 Inspired Healthcare Outcomes Award for her work in reducing MRSA infection rates. In 2015, she received the ICE Award (Increasing Clinical Effectiveness) from the Clinical Laboratory Management Association for her work in reducing hospital acquired infections. Spencer, M., Uettwiller-Geiger, D., Sanguinet, J., Johnson, H. B., & Graham, D. (2016). Infection preventionists and laboratorians: Case studies on successful collaboration. American Journal of Infection Control, 44(9), 964-968. Christenson, R. H., Jacobs, E., Uettwiller-Geiger, D., Estey, M. P., Lewandrowski, K., Koshy, T., Kupfer, K., Li, Y., & Wesenber, J. (2017). Comparison of 13 Commercially Available Cardiac Troponin Assays in a Multicenter North American Study. The Journal of Applied Laboratory Medicine, 1(5), 544-561. Visiun, Inc. is the leading provider of performance analytics to the laboratory industry. Headquartered in Ann Arbor, Michigan, Visiun has been providing services to the laboratory industry for over six years, with hundreds of laboratories installed across the United States. Performance Insight™, Visiun's core product, provides laboratory managers with a comprehensive suite of analytics that deliver immediate improvements in performance, efficiency, and quality. For more information, please visit http://www.visiun.com.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Clinical Chemistry Analyzers Market 2017-2021" report to their offering. The global clinical chemistry analyzers market to grow at a CAGR of 2.24% during the period 2017-2021. The report, Global Clinical Chemistry Analyzers Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. The latest trend gaining momentum in the market is focus on fully automated clinical chemistry analyzers. In the last few years, clinical chemistry analyzers have been undergoing major changes in design and function. Typically, the POC monitoring of anticoagulation is done in outpatient anticoagulation clinics, cardiac surgery units, intensive care units (ICUs), and dialysis units with the help of different technologies. There are fully automated clinical chemistry analyzers available in the market that can perform functions such as recognition of sample and reagent bottles, tube sampling, cap piercing, automatic re-run, and dilution. According to the report, one of the major drivers for this market is rising demand for automation and integration of multiple processes. Clinical laboratories rely on progressing levels of automation to solve persistent challenges that include lack of skilled personnel, pressures to maintain cost while increasing productivity, and errors associated with manual processes. For more information about this report visit http://www.researchandmarkets.com/research/bhsz8m/global_clinical


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "North America Clinical Chemistry Analyzer Market - Opportunities and Forecast, 2014 - 2022" report to their offering. A clinical chemistry analyzer is use to analyze blood serum, plasma, urine and other body fluids with the help of various measurement technologies such as photometric and colorimetric testing, ion-selective potentiometry, and latex agglutination. The chemical analyzers can be employed in small point-of-care clinics and high-throughput clinical labs to determine concentration of metabolites, proteins, sugars, and electrolytes and others. In this device, samples are first inserted in a slot or tray, programmed through a keypad, and results are displayed on a screen. The analyzers are available as bench top models, compact bedside models, and high-throughput floor-based units. Clinical analyzers are used to monitor diseases such as diabetes, testing for metabolic functions or cardiac markers, and drugs-of-abuse testing. Technological advancements in clinical chemistry analyzers enable users to obtain accurate results in less time. The clinical chemical analyzers market in North America is expected to register a significant growth due to rising healthcare expenditure, increasing incidences of contagious diseases, such as tuberculosis, malaria, and growing records of criminal activities. The market is also poised to grow concurrently with the development of new assays, advent of customized analyzers and development of software, which would increase testing speed and degree of automation. However, high cost of device and shortage of skilled professionals are the restraining factors of the market. North America clinical chemistry analyzer market is segmented into of type, technology, end user, and geography. On the basis of type, the market is classified into semi-automated and fully-automated analyzers. Further, the fully automated analyzer market is classified into entry level, medium throughput, large high throughput, and ultra large high throughput based on tests per hour. Based on technology, the market is categorized into wet and dry chemistry. End user market is classified into academic research institutes, diagnostic laboratories, hospitals, and other end users. The market is divided geographically into U.S., Canada, and Mexico. The major manufacturers of clinical chemistry analyzers are Abbott Diagnostics, Roche Diagnostics, Beckman Coulter, Siemens AG, Thermo Fisher Scientific, Ortho-Clinical Diagnostics, Randox Laboratories Ltd., ElitechGroup, Horiba, and Mindray. Some of the key strategies, such as partnerships, mergers, joint ventures, and new product launches have been implemented by them to strengthen their position in the industry. For more information about this report visit http://www.researchandmarkets.com/research/7b626n/north_america


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Americas Clinical Chemistry Analyzer Market - Opportunities and Forecasts, 2014 - 2022" report to their offering. A clinical chemistry analyzer is used to determine concentration of metabolites, proteins, sugars, and electrolytes in samples of bodily fluids, such as plasma, serum, urine, and others. It is a device where samples are first inserted in a slot or tray, then tests are programmed through a keypad, and results are displayed on a screen. An analyzer diagnoses and treats fatal diseases, such as diabetes, HIV, cancer, hepatitis, thyroid problems, and others. Clinical conditions of liver function, kidney function, and hemoglobin levels can be determined with the help of an analyzer. Technological advancements in clinical chemistry analyzers enable users to obtain accurate results in less duration. Rising healthcare expenditure, increasing aging population, contagious diseases, such as tuberculosis, malaria, and increase in criminal activities are factors driving the growth of the Americas clinical chemistry analyzer market. However, high cost of device and shortage of skilled professionals are the restraining factors in this market. Laboratory automation, growing infrastructure facilities and technological advancements are likely to create opportunities for the market. The Americas clinical chemistry analyzer market is segmented in terms of type, technology, end user, and geography. On the basis of type, the market is classified into semi-automated and fully-automated analyzers. Furthermore, the fully automated analyzer market is classified into entry level, medium throughput, large high throughput, and ultra large high throughput based on tests per hour. Based on technology, the market is categorized into wet and dry chemistry. The market is segmented based on end user into academic research institutes, diagnostic laboratories, hospitals, and other end users. The market is geographically categorized into the U.S., Canada, Chile, Mexico, and Rest of America (RoA). The major manufacturers of clinical chemistry analyzers are Abbott Diagnostics, Roche Diagnostics, Beckman Coulter, Siemens AG, Thermo Fisher Scientific, Ortho-Clinical Diagnostics, Randox Laboratories Ltd., ElitechGroup, Horiba, and Mindray. Various strategies, such as partnerships, mergers, joint ventures, and new product launches have been implemented by the leading market players to strengthen their position in the industry. For more information about this report visit http://www.researchandmarkets.com/research/qgdfs4/americas_clinical


News Article | November 11, 2016
Site: www.prnewswire.co.uk

The report "Veterinary Surgical Instruments Market by Product (Sutures, Foreceps, Scissors, Electrosurgery Instruments, Cannulas), Animal (Canines, Felines, Large Animals) & Applications (Soft tissue, Sterilization, Gynecology, & Orthopedic Surgery) - Forecast to 2021", published by MarketsandMarkets, analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, and Rest of the World. Browse 175 market data tables and 32 figures spread through 244 pages and in-depth TOC on "Veterinary Surgical Instruments Market " Early buyers will receive 10% customization on this report. The veterinary surgical instruments market witnessed healthy growth during the last decade and is expected to grow at a CAGR of 6.6% between 2016 and 2021 to reach 1029.0 Million by 2021. The growth in this market is majorly attributed to factors such as rising animal healthcare expenditure, rising pet adoption, increasing number of veterinary practitioners and their growing income levels in developed regions, and increasing demand for pet insurance. The global veterinary surgical instruments market is segmented based on product, animal, application, and geography. Based on product type, the market is segmented into sutures, staplers and accessories, handheld devices, electro-surgery instruments, and others. The handheld devices are further segmented into forceps, scalpels, surgical scissors, hooks & retractors, and trocars & cannulas. Based on animal type, the market is segmented into small animals and large animals. The small animals segment is further segmented into canines, felines, and other small animals, while the large animals segment is further segmented into equines and other large animals. Based on the application the veterinary surgical instruments market is segmented into soft- tissue surgery, sterilization surgery, gynecology & urology, dental surgery, orthopedic surgery, ophthalmic surgery and others. Similarly, on the basis of geography, the veterinary surgical instruments market is segmented into Europe, North-America, Asia-Pacific, and Rest of the World. In 2015, sutures, staplers, and accessories accounted for the largest share of the global veterinary surgical instruments. However, electro-surgery instruments segment is expected to witness the highest growth over the next five years. The high growth in this segment can be attributed to the advantages such as easy handling, high sensitivity, accuracy, and rapid healing offered by the electrode pencils used in various surgeries of small and large animals. North America is the largest regional segment for veterinary surgical instruments owing to the well-established animal healthcare market. The largest share of this regional segment is driven by rising companion animal adoption and healthcare expenditure, growing number of veterinary practitioners and their income levels, and rising demand for pet insurance. However, the market in the Asia-Pacific region is expected to grow at the highest CAGR, owing to rising pet adoption and increasing demand for animal-derived food products in India and China. The market players, namely, B. Braun Vet Care GmbH (Germany), Medtronic Plc. (Ireland), Ethicon Inc. (U.S.), and JORGEN KRUSSE A/S (Denmark) held the major share of the veterinary surgical instruments market and will continue to dominate the market between 2016 and 2021. Some of the major players operating in this market are Jorgensen Laboratories (U.S.), Smiths Group Plc (U.K.), Neogen Corporation (U.S.), Integra LifeSciences Holdings Corporation (U.S.), Ethicon Inc. (U.S.), Steris Corporation (U.S.), DRE Veterinary (U.S.), GerMedUSA, Inc. (U.S.), Surgical Holdings (U.K.), Sklar Surgical Instruments (U.S.), World Precision Instruments, Inc. (U.S.), Surgical Direct (U.S.), Antibe Therapeutics Inc. (Canada), and iM3 (U.S.). Veterinary Diagnostics Market by Product (Instruments, Consumables, Services) by Technology (Diagnostic Imaging, Clinical Chemistry, Immunodiagnostics, Molecular Diagnostics) by Animal (Dogs, Cats, Horses, Cattle, Pigs, Poultry) - Global forecast to 2021 MarketsandMarkets is the world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


News Article | November 10, 2016
Site: marketersmedia.com

— China In-Vitro Diagnostics (IVD) market is among the fastest growing in the world. It is anticipated that China IVD market will more than triple by 2020 from the 2014 level. With an aging population, a rapidly growing middle class and a government encouraging preventive care, China has the potential for more dramatic growth in the future. Further, the average Chinese consumer is now willing and able to pay more for healthcare than a decade years ago. Hence, China has the potential for more dramatic growth in the future. China IVD Market Segment Wise Analysis: Immunoassay is the leading segment in China IVD market. Immunoassay is likely to maintain its dominant position in the forecasting period as well. Clinical Chemistry holds the 2nd position in China IVD market being followed by Molecular Testing. SMBG market accounted for XXX percent market share in 2014. Microbiology and Hematology market are competing closely with XXX percent and XXX percent market share respectively in 2014. China IVD Market Company Analysis: In China IVD market, Roche Diagnostics is the leader with XXX percent market share in 2014. Sysmex Corporation and Mindary Medical are other top two players in the China IVD market. At present many local players are present in China IVD market and their combined market share was XXX percent in 2014. "China IVD Market and Forecast to 2020" is a 86 page report with 34 Figures and 1 Table. This report studies in details the China IVD Market - Application Segment Wise, China IVD Market - Company Sales, Development Environment and Regulatory Status in China IVD market and Driving Factors and Challenges for China IVD Market. The China In Vitro Diagnostics (IVD) Market has been analyzed from 4 View Points: • Market and Forecast (2007 - 2020) • Segment Wise Market & Forecast (2007 - 2020) • Development Environment and Regulatory Status in China IVD market • Company Wise IVD Sales & Forecast (2010 - 2020) China IVD Market - 8 Application Segments Covered in the Report: 1. Clinical Chemistry Market 2. Immunoassay Market 3. Hematology Market 4. Coagulation Market 5. Microbiology Market 6. Molecular Testing Market 7. Self-Monitoring of Blood Glucose (SMBG) Market 8. Point of Care Testing (POCT) Market Purchase a copy of this “China IVD Market” research report at USD 1000 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=481213. The Companies covered in the report are as follows: • Roche Diagnostic • Sysmex Corporation • Mindray Medical International Limited • Shanghai Kehua Bio-Engineering Co. Ltd. • Others Profiles of Private Clinical Labs and Diagnostic Services Companies in China • Zhejiang Di'an Diagnostics Technology Co., Ltd • ADICON Clinical Laboratories • Guangzhou Kingmed Diagnostics Center Co. Ltd. • Kindstar Global (Privately held) • BGI-Shenzhen (Privately held) • OriGene Technologies (Privately held) Major Points from Table of Contents (http://www.marketreportsonline.com/481213-toc.html) provided in China IVD Market: 1. Executive Summary 2. China IVD Market and Market Share Analysis (2007 - 2020) 3. China IVD - Segments Wise Market and Forecast (2007 - 2020) 4. Development Environment of Chinese IVD Industry 5. Profile of In-vitro Diagnostic Reagents Registration Control 6. China IVD Market - Company Wise Sales Analysis (2010 - 2020) 7. Profiles of Select Private Clinical Labs and Diagnostic Services Companies 8. China IVD Industry Drivers 9. China IVD Industry Challenge Other Related Reports on IVD (In Vitro Diagnostics) Market: China In Vitro Diagnostics (IVD) Market, Forecast & Companies Analysis: This is 3rd edition report on In Vitro Diagnostics sector by Renub Research. Report titled “China In Vitro Diagnostics (IVD) Market, Forecast & Companies Analysis” provides a comprehensive assessment of the fast–evolving, high–growth IVD Market in China. This 77 page report with 34 Figures studies the China IVD market from 4 view points: 1) Market and Forecast, 2) Segment Wise Market & Forecast, 3) Development Environment & Regulatory Status in China IVD market, 4) Company Wise IVD Sales & Forecast Complete report available at http://www.marketreportsonline.com/376729.html. Global In-Vitro Diagnostics (IVD) Market Report: 2015 Edition: The diagnostic industry is widely classified into two types: In-vitro diagnostics and In-vivo diagnostics. In-vitro tests are executed in glass test tubes, while In-vivo diagnostics tests are executed inside a patient’s body. IVD products are indeed designed and produced for collecting samples derived from the patient’s body and scrutinizing them outside, which are commonly conducted in hospitals, clinics and labs and in personal settings. Apart from the application of IVDs in medical diagnosis and health screening such as checking blood of signs for infections, or urine for the presence of glucose, they are also used in genetic testing, genomics, veterinary diagnostics, food testing, environmental testing, and research. Complete report with table of contents available at http://www.marketreportsonline.com/434386.html. China In Vitro Diagnostics (IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021: The in–vitro diagnostics(IVD) market in China has been growing rapidly in the past few years and is expected to grow steadily in the next few years, with major growth potential in segments such as infectious disease testing, chronic disease testing and diagnosis in early stages of disease. Roche is the leading company with more than XX% market share in the China IVD market and is expected to hold its strong position in the market. Sysmex Corporation and Abbott Laboratories are the other top two players in the China IVD market. Mindray and Shanghai Kehua Bioengineering(KHB) are another major participant in this market with a good hold in clinical chemistry, immunoassay and molecular testing segments providing varieties of reagents nationwide and semi–auto and automatic biochemistry analyzers to low and mid–end market users. Complete report available at http://www.marketreportsonline.com/496440.html. For more information, please visit http://www.marketreportsonline.com/contacts/purchase.php?name=481213


News Article | February 15, 2017
Site: www.newscientist.com

A FAST test for genetic disorders means women could learn about the future health of their baby as early as 6 weeks into pregnancy. The test for single-gene disorders, which are collectively more common than Down’s syndrome, could become available within five years. This would enable prospective parents to choose whether to proceed with a pregnancy if conditions like muscular dystrophy or Huntington’s disease are detected. “This is just sensational – I’m completely blown away,” says Andrew McLennan, a specialist in prenatal diagnosis at Royal North Shore Hospital in Sydney, Australia. Many inherited diseases, including sickle cell anaemia, haemophilia and cystic fibrosis, are caused by mutations within a single gene. We know of 10,000 single-gene conditions and together, they affect about one in 100 births. At the moment, options for prospective parents are limited. Embryos can be screened using pre-implantation genetic diagnosis (PGD), if couples opt for IVF. Those who conceive naturally can have tests like amniocentesis, but these carry a small risk of miscarriage, and detect a limited number of genetic disorders. “Abortion isn’t the only option. Test results could help reduce the effects of a genetic disorder” But the speed and ease of safer tests is improving. The non-invasive prenatal test (NIPT) for Down’s syndrome is available in over 60 countries, including the US and Australia, and it is being trialled in some UK hospitals. Now the team that developed NIPT has found a similar way to detect single-gene diseases. The test, developed by Rossa Chiu at the Chinese University of Hong Kong, and her colleagues, can detect almost any single-gene disorder in the first 6 to 10 weeks of pregnancy. Guided by DNA from parent blood samples, the test looks for increases in the level of mutations associated with a particular condition in the mother’s blood once she is pregnant. In theory, any hospital pathology lab could run the test, producing results in one to two weeks. In a study of pregnant women at risk of having a child with a single-gene disorder, the test accurately predicted the condition in all 12 fetuses whose DNA they were able to test (Clinical Chemistry, doi.org/bv3h). In the UK, the Don’t Screen Us Out campaign has voiced concerns that NIPT for Down’s syndrome could lead to the number of babies born with the condition to decrease by more than 10 per cent. The group says this would have a long-term effect on the Down’s community, and will allow an informal kind of eugenics. Advances in prenatal screening often spark controversy because of concerns that they might promote intolerance of diversity, McLennan says. “But this is not a negative eugenics campaign,” he says. “This is about choice. It’s about being given the opportunity to have information, to have appropriate counselling, and to make decisions.” “Some of the cystic fibrosis community are very against tests that are post-conception because they say ‘my life is pretty good and I wouldn’t exist if that test was around when I was born’,” says Nettie Burke from Cystic Fibrosis Australia. “But there are mothers who have said to me ‘I wish I’d known, because I would have had an abortion’.” But abortion isn’t the only option. In some cases, test results could help reduce the effects of a genetic disorder. Some of the symptoms of congenital adrenal hyperplasia, such as genital ambiguity, can be alleviated if a mother is given a steroid before 9 weeks of pregnancy. Thalassemia blood disorders can be treated with blood transfusions if given soon after birth. “In the future, some disorders may also be treatable in utero using gene therapies,” says Chiu. The test will first be developed for couples with family histories of genetic disorders, but Chiu hopes it will later be incorporated into universal screening programmes. “The potential for this is just phenomenal,” says McLennan. This article appeared in print under the headline “Early fetal gene test”


News Article | December 6, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global In Vitro Diagnostics market is accounted for $61.65 billion in 2015 and is expected to reach $94.57 billion by 2022 growing at a CAGR of 6.3%. Technologically advanced healthcare and consumer spending in market is helping the market growth. Polluted environment and contaminated surroundings are leading to increase in number of chronic disease and infections, these all factors are favoring the market to grow. Moreover widely spread knowledge and cost effectiveness are also driving the market. But stringent regulations and reimbursement issues are hampering the market growth. However Infectious disease in application segment is anticipated to grow at considerable pace due to rise in amount of infectious diseases and it is followed by HIV/AIDS application. Whereas Laboratories in end-user segment is estimated to grow fast because of rise in number of laboratories, followed by Point of Care Diagnostics. North America being the largest revenue market, Asia Pacific is expected to grow fast due to increasing number of End-User applications. Some of the major key players in the market are Roche Diagnostics  Bio-Rad Laboratories, Inc., Johnson and Johnson , Biomérieux, Siemens Healthcare, Abbott Laboratories, Inc., Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Danaher Corporation, Sysmex Corporation, Becton, Dickinson and Company, Cepheid Inc , Alere Inc., Novartis and Leica Biosystems. Technologies Covered: • Immunochemistry/Immunoassays   o Elisa § Chemiluminescence Immunoassays (CLIAs) § Colorimetric Immunoassays (CI) § Fluorescence Immunoassays (FIA) o Western Blot o Rapid Tests o Radioimmunoassay’s (RIA) o Elispot • Coagulation and Hemostasis   • Molecular Diagnostics (MDX)   o DNA Sequencing & Next-Generation Sequencing o Hybridization o Isothermal Nucleic Acid Amplification Technology (INAAT) o Microarrays o Polymerase Chain Reaction (PCR) o Other Molecular Diagnostics • Hematology   • Microbiology   • Clinical Chemistry   o Electrolyte Panels o Basic Metabolic Panel o Lipid Profiles o Liver Panels o Renal Profiles o Specialty Chemical Tests o Thyroid Function Panels • Other Technologies Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific       • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements

Loading Clinical Chemistry collaborators
Loading Clinical Chemistry collaborators